Ohr Pharmaceutical Inc (NASDAQ:OHRP) Big Money Positioning Change, Sentiment at 0.67

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) Corporate Logo

“Big money” Positions

“Big money sentiment for Ohr Pharmaceutical Inc (NASDAQ:OHRP) in Q2 2018 decreased to 0.67, according to SEC filings. That’s down -0.15, from 2018Q1’s 0.82. 6 active investment managers opened new and increased stock positions, while 9 cut down and sold their stakes in Ohr Pharmaceutical Inc so the sentiment fall. These funds own 5.00 million shares, that’s down from 5.09 million shares in 2018Q1. Funds holding Ohr Pharmaceutical Inc in top 10 was flat from 0 to 0 for the same number . In total 4 funds closed positions, 5 reduced and 4 increased. Also 2 funds bought new Ohr Pharmaceutical Inc stakes.

Largest Ohr Pharmaceutical Inc Shareholders

Garrison Bradford & Associates Inc owns 451,200 shares in Ohr Pharmaceutical Inc as of Q2 2018. Ohr Pharmaceutical Inc’s shareholder Bank Of America Corp De owns 500 shares as of Q2 2018. Bank Of New York Mellon Corp reported 34,472 shares. Blackrock Inc. revealed 412,666 shares position in Ohr Pharmaceutical Inc. The Pennsylvania-based fund Bryn Mawr Trust Co holds 10,000 shares or 0% of their fund portfolio.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease.The company has $7.91 million market cap. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.Last it reported negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

The stock increased 4.32% or $0.0058 during the last trading session, reaching $0.14.Currently OHR Pharmaceutical, Inc. is downtrending after 74.70% change in last December 8, 2017. OHRP has 647,349 shares volume. OHRP underperformed by 90.32% the S&P 500.

Wells Fargo & Mn has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). California Pub Employees Retirement Sys has 78,800 shs. Blackrock Inc reported 412,666 shs stake. Fincl Bank Of America De has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Bryn Mawr Trust has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Morgan Stanley holds 0% or 5,650 shs. Janney Montgomery Scott Limited Liability holds 0% or 10,500 shs in its capital. Jpmorgan Chase And has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 2,800 shs. Bankshares Of Ny Mellon Corp owns 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 34,472 shs. Pnc Fincl Grp Incorporated holds 21 shs. Geode Cap Mgmt Ltd Liability Com reported 268,161 shs. Gp One Trading L P, Illinois-based fund reported 54,303 shs. Creative Planning holds 66,000 shs or 0% of its capital. 410 are owned by Royal National Bank & Trust Of Canada. Garrison Bradford & Associates Inc holds 0.07% of its capital in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 451,200 shs.

For more OHR Pharmaceutical, Inc. (NASDAQ:OHRP) news brought out briefly go to: Seekingalpha.com, Nasdaq.com, Seekingalpha.com, Globenewswire.com or Benzinga.com. The titles are as follows: “Ohr Pharmaceutical: A Compelling Acquisition Candidate And The Best Risk/Reward In The Wet AMD Space – Seeking Alpha” brought out on December 01, 2017, “Ohr Pharmaceutical Provides Update on Squalamine Study – Nasdaq” on April 11, 2017, “Phase III Drugs: Teetering Between Success And Failure – Seeking Alpha” with a publish date: February 05, 2016, “Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD – GlobeNewswire” and the last “Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings – Benzinga” with publication date: August 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.